

# EARLY REAL-WORLD OUTCOMES OF CHONDROITIN SULFATE AND BOVINE COLOSTRUM INTRAVESICAL INSTILLATIONS IN RECURRENT URINARY TRACT INFECTION AND BLADDER PAIN SYNDROME

## KEY FINDINGS

≈60%

Pain reduction

≈56%

BPIC-SS reduction

50%

6/12 women with rUTI without documented recurrence



Grupo quironsalud

MONZÓN FALCONI JF<sup>1</sup>, BATISTA MIRANDA JE<sup>2</sup>, HERREROS ELORZA P<sup>2</sup>, GONZALEZ LUQUE E<sup>1</sup>, GONZALEZ MUÑOZ A<sup>1</sup>, LEKUE MANTZIZIDOR I<sup>1</sup>

[www.ics.org/2026/abstract #680](http://www.ics.org/2026/abstract #680)


Recurrent UTI and non-Hunner BPS/IC cause substantial symptom burden. Clinical evidence for intravesical chondroitin sulfate plus bovine colostrum remains limited.

**Objective:** To describe clinical outcomes and documented adverse events associated with this formulation in two separate cohorts.




**Methods** Prospective, two-center, uncontrolled pilot.  
19 women: 7 BPS/IC and 12 rUTI  
Four weekly instillations + weeks 8/12  
50 mL: 300 mg CS + 900 mg bovine colostrum  
Cohort-specific exploratory analyses  
Ethics Committee CEIC 2025/87-URO-CMT

## Patient-Reported Outcomes Over 12 Weeks

BPS/IC cohort • Lower scores indicate clinical improvement



### Baseline characteristics




Consistent symptom improvement across all patient-reported measures by Week 12.

Values are mean ± SD. Percentage reduction is based on paired observations.

## Clinical Outcomes in Women with Recurrent UTI

Treatment completion, recurrence patterns, recurrence-free survival, and safety



### Baseline characteristics

|                                            |                                     |                                                    |               |
|--------------------------------------------|-------------------------------------|----------------------------------------------------|---------------|
| Age, years                                 | 62.5 ± 16.2; median 69; range 26–78 | Postcoital UTI pattern, n/N (%)                    | 3/12 (25.0%)  |
| History of antibiotic prophylaxis, n/N (%) | 11/12 (91.7%)                       | Prior nutraceuticals/probiotics/D-mannose, n/N (%) | 11/12 (91.7%) |
| Postmenopausal status, n/N (%)             | 9/12 (75.0%)                        | Prior autovaccine treatment, n/N (%)               | 5/12 (41.7%)  |

**SAFETY** Treatment-related adverse events: 0/12 (0%)

Half of the cohort remained recurrence-free during available follow-up, while all non-completers experienced an early recurrence.

Values are n/N (%), mean ± SD, or median (range), as indicated.

**Conclusions:** Intravesical chondroitin sulfate plus bovine colostrum was associated with improvements in pain and bladder symptoms among evaluable BPS/IC, and rUTI recurrence.